Capital Investment Advisors LLC Has $14.01 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Capital Investment Advisors LLC lowered its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 7.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 229,731 shares of the biopharmaceutical company's stock after selling 18,061 shares during the quarter. Capital Investment Advisors LLC's holdings in Bristol-Myers Squibb were worth $14,011,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Truist Financial Corp raised its stake in shares of Bristol-Myers Squibb by 3.9% in the fourth quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company's stock valued at $90,335,000 after acquiring an additional 60,365 shares in the last quarter. Quilter Plc raised its position in Bristol-Myers Squibb by 56.6% in the 4th quarter. Quilter Plc now owns 107,818 shares of the biopharmaceutical company's stock valued at $6,098,000 after purchasing an additional 38,977 shares in the last quarter. Advyzon Investment Management LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $458,000. Leo Wealth LLC grew its position in shares of Bristol-Myers Squibb by 51.5% during the fourth quarter. Leo Wealth LLC now owns 14,965 shares of the biopharmaceutical company's stock worth $846,000 after buying an additional 5,085 shares in the last quarter. Finally, Covenant Asset Management LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $279,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BMY. UBS Group decreased their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Argus raised Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Piper Sandler began coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction dated Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Up 1.2%

BMY traded up $0.60 on Monday, reaching $49.01. 9,861,388 shares of the company traded hands, compared to its average volume of 13,044,821. The company has a market cap of $99.74 billion, a price-to-earnings ratio of -11.09, a PEG ratio of 2.07 and a beta of 0.38. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The stock's 50 day moving average price is $49.34 and its 200-day moving average price is $55.02. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's revenue was down 5.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($4.40) earnings per share. On average, sell-side analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.